- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
Patent holdings for IPC class C07D 207/08
Total number of patents in this class: 688
10-year publication summary
|
50
|
43
|
42
|
52
|
59
|
45
|
47
|
53
|
41
|
28
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| F. Hoffmann-La Roche AG | 7920 |
13 |
| Ligand Pharmaceuticals Incorporated | 169 |
13 |
| Corsair Pharma, Inc. | 37 |
12 |
| Tetraphase Pharmaceuticals, Inc. | 51 |
12 |
| Theravance Biopharma R&D IP, LLC | 458 |
12 |
| Bristol-myers Squibb Company | 4884 |
11 |
| Global Blood Therapeutics, Inc. | 183 |
11 |
| The Regents of the University of California | 19943 |
10 |
| Takeda Pharmaceutical Company Limited | 2696 |
10 |
| Atrogi AB | 53 |
9 |
| Eli Lilly and Company | 3848 |
9 |
| Merck Sharp & Dohme LLC | 3742 |
9 |
| Pfizer Inc. | 3380 |
8 |
| Wave Life Sciences Ltd. | 169 |
8 |
| Theravance, Inc. | 66 |
7 |
| Novartis AG | 10829 |
6 |
| Hoffmann-La Roche Inc. | 3428 |
6 |
| Janssen Pharmaceutica N.V. | 3384 |
6 |
| Ambrx, Inc. | 182 |
6 |
| Biogen MA Inc. | 892 |
6 |
| Other owners | 504 |